Sharon Li, MD
Hematology & Oncology · Newark, NJNPI 1386030575
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,665 of the $1,748 with a category attached, or 95.2%. AstraZeneca accounts for 95.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $1,681 and has fallen 98.9% since, to $18 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NJ, where the typical reported total is $2,686.
Across 4 payments — averaging $437.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Stryker$49
- Merck$18
- Jazz Pharmaceuticals Inc.$16
Across 2 payments — averaging $87,464 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$175K
What the payments were for
- Consulting fees$1,66595%
- Food & beverage$835%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $1,665 |
| Stryker | 1 | $49 |
| Merck | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$1,665
How this compares
$1,748 in reported general payments places this provider in the 40th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 12 | $82,557 |
| EliquisApixaban | 24 | $21,331 |
| XareltoRivaroxaban | 21 | $11,514 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 19 | $220 |
| Gabapentin | 15 | $77 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Newark
- Alice CohenNewark$21K
- Robert SpiegelWestfield$864K
- Amit PatelJersey City$770K
- Joshua StraussSpringfield$739K
- Charles FarberMorristown$609K
- Michael ScolaMorristown$506K
- Eshan PatelSomerville$420K
- Arturo Loaiza-BonillaPennington$406K
- Ashish ShahSpringfield$394K
- Carl HenningsonManasquan$349K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.